The Moat Index
Compare moats, side by side.
Two to four companies, scored on the same five investor questions from their SEC filings — so the comparison is apples to apples. The method is fully public.
ABCL · Healthcare · No moat
Doesn't clear the bar
The pricingPower component abstained: Not enough years of gross-margin data to score pricing power. The other four 20% weights were renormalized over the scored 80%.
| Measure | ABCL | VYNE | ESMC | KMTS |
|---|---|---|---|---|
| Moat Score (0–100) | 38 (highest) | 38 (highest) | 38 (highest) | 38 (highest) |
| Methodology version | moat-index@2.0.0 | moat-index@2.0.0 | moat-index@2.0.0 | moat-index@2.0.0 |
| Business trend | 57 | 20 | 26 | 70 (highest) |
| Pricing power | — | 70 | 75 (highest) | 40 |
| Returns on capital | 15 (highest) | 0 | 4 | 0 |
| Balance-sheet safety | 55 (highest) | 55 (highest) | 37 | 55 (highest) |
| Capital discipline | 24 | 44 | 47 (highest) | 24 |
| Price vs. high estimate | No price data | No price data | 101% above high estimate | No price data |
| Market cap | $1.7B | $26.9M | $1.5M | $1.4B |
| Moat tier | No moat | No moat | No moat | No moat |
| Filings as of | FY2025 | FY2025 | FY2025 | FY2026 |